Human Pheromone Sciences Announces Third Quarter Results

(Royalties from an expanded license agreement result in quarterly profit and improvement in nine month results)


SAN JOSE, Calif., Nov. 13  /PRNewswire-FirstCall/ -- Human Pheromone Sciences, Inc. (OTC:EROX) (BULLETIN BOARD: EROX)  ("HPS" or "the Company") today announced results for the three and nine month periods ended September 30, 2009. For the three months ending September 30, 2009, net revenues of $273,000 represented a 4% increase from the revenues of $262,000 in the prior year period, and resulted in net income of $10,000 ($0.00 per share) as compared with a net loss of $30,000 ($0.01 per share) for the same period of 2008.  For the nine month period ending September 30, 2009, net revenues of $662,000 were 13% lower than the previous year's $764,000, resulting in a net loss of $255,000 ($0.06 per share) as compared with a net loss of $181,000 ($0.04 per share) in the first nine months of 2008.

According to a Company spokesperson, "the slight increase in revenues for the quarter is attributable to royalties generated under the expansion of our agreement with an additional U.S. subsidiary of the international chemical and consumer giant Schwarzkopf and Henkel (Dial Corporation). The launch of the Dial Body Wash Product containing our technology is very creative and exciting, and their website dedicated to these products, getmagnetic.com., is incredibly innovative, informative and entertaining.  Somewhat offsetting these actual revenue increases, was a decrease in recognition of deferred revenue associated with the agreement entered into with Johnson & Johnson in 2006. The increased revenues from the higher margin royalty revenues contributed to net income of $10,000  in the current year third quarter as compared with a $30,000 loss in the same quarter lat year."

Human Pheromone Sciences, Inc. is a technology-based company, whose proof-of concept products included prestige-priced fragrances and toiletries and environmental products sold under the Natural Attraction®, REALM®, innerREALM® and  EROX® trademarks.  These products contain mood-enhancing compounds, whose efficacy has been validated at leading universities around the world, and whose use is covered under United States and foreign patents. The Company is also involved in research and product development efforts on new compounds that have been previously identified as stimulating the emotional centers of the human brain. Further information is available on line at http://www.erox.com/.

The statements in this news release may contain forward-looking statements that involve risks and uncertainties that could cause results to differ from predicted results.  Further information on factors that could affect the Company's results is detailed in the Company's annual report to shareholders on Form 10-K for the year ended December 31, 2008, and Form 10-Q for the three and nine months ended September 30, 2009,  as filed with the Securities and Exchange Commission.  The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements.

                               Tables follow



                         HUMAN PHEROMONE SCIENCES, INC.

                           Condensed Balance Sheets
                            (Dollars in thousands)



                                        September 30,          December 31,
                                             2009                  2008
                                             ----                  ----
                                         (Unaudited)             (Note 1)
  Assets

  Cash and cash equivalents           $       370            $        907
  Accounts receivable                         168                      52
  Inventories                                  45                      39
  Other current assets                         33                      58
  Property and equipment, net                   1                       2
                                              ---                     ---

  Total                               $       617            $      1,058
                                      ===========            ============

  Liabilities and shareholders' equity

  Accounts payable                    $        15            $         19
  Other current liabilities                   130                     131
  Deferred income - current                   220                     297
  Deferred income - non-current               188                     324
  Common stock                             21,075                  21,043
  Accumulated deficit                     (21,011)                (20,756)
                                          -------                 -------

  Total                               $       617            $      1,058
                                      ===========            ============

  Note 1 - Derived from audited financial statements



                             HUMAN PHEROMONE SCIENCES, INC.

                          Condensed Statements of Operations
                                     (Unaudited)
                     (Dollars in thousands, except per-share data)

                          Three months ended            Nine months ended
                             September 30,                 September 30,
                             ------------                  -------------
                        2009              2008          2009          2008
                        ----              ----          ----          ----

  Net revenue       $    273          $    262       $   662       $   764

  Cost of goods
   sold                   37                86           167           240
  Research and
   development            17                10            55            33
  Selling, general
   and
   administrative        209               203           696           696
                         ---               ---           ---           ---
  Income (loss)
   from operations        10               (37)         (256)         (205)

  Other income             -                 7             2            25


  Provision for
   income taxes            -                 -             1             1
                         ---               ---           ---           ---
  Net income
   (loss)           $     10          $    (30)      $  (255)      $  (181)
                    ========          ========       =======       =======

  Income (loss)
   per share -
     Basic:         $   0.00          $  (0.01)      $ (0.06)      $ (0.04)
                    ========          ========       =======       =======

     Fully
      diluted:      $   0.00          $  (0.01)      $ (0.06)      $ (0.04)
                    ========          ========       =======       =======


  Weighted average
   common shares
   outstanding-
     Basic:            4,152             4,152         4,152         4,152
                       =====             =====         =====         =====
     Fully
      diluted:         5,062             4,152         4,152         4,152
                       =====             =====         =====         =====

  Net loss per share is based on the weighted average number of common
  shares and common equivalents outstanding during each period.  Certain
  common stock equivalents are excluded when their effect would be
  anti-dilutive.


DATASOURCE: Human Pheromone Sciences, Inc.



CONTACT:  William P. Horgan, Chairman, CEO of Human Pheromone Sciences,

Inc., [phone]



Web Site:  http://www.erox.com/ 

Copyright